A carregar cotações...
Previsão
| Comprar |
13 |
| Manter |
2 |
| Vender |
1 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Cellectis reports quarterly loss per share of $0.26 and declining revenue
Cellectis reported earnings per share of -$0.26 for the most recent quarter, after -$0.080 in the year-ago quarter. Quarterly revenue fell to $10.4 million (-17.74% versus $12.6 million). For the full year, the company shows a loss per share of -$0.670, while annual revenue rose sharply to $73.17 million (±76.61% versus $41.43 million). » Mais em finanzen.net
Cellectis beats Q4 2025 revenue and EPS forecasts, stock rises
Cellectis reported Q4 2025 EPS of -$0.19 (forecast -$0.2948) and revenue of $17.1 million (forecast $10.02 million), both well above expectations. The stock rose 2.01% in premarket trading to $3.55. Cash resources of $211 million secure the company’s financial runway into the second half of 2027. The company highlights progress on the Lasme‑Cel and Eti‑Cel programmes and the validation of internal manufacturing capacities. » Mais em de.investing.com
Cellectis: arbitration panel partially terminates license agreement with Servier
An arbitration panel has partially terminated the 2019 license, development and commercialization agreement between Cellectis and Servier. The decision specifically concerns the product UCART19 V1 (also ALLO-501) and obliges Cellectis, upon request, to enter into good-faith negotiations with Allogene regarding a direct licensing arrangement. All other claims brought in the arbitration were dismissed. » Mais em de.investing.com
Cellectis achieves breakthrough in non-viral gene insertion method
Cellectis and Moligo present in Nature Communications a non-viral gene insertion method for hematopoietic stem and progenitor cells (HSPCs) based on enzymatically produced circular single-stranded DNA (CssDNA). The circular ssDNA format reached insertion rates above 40% and was 3- to 5-fold more efficient than linear ssDNA; in mouse models, CssDNA-edited HSPCs showed better expansion and retention of edits than with AAV6. The collaboration aims to provide a scalable alternative to viral vectors and strengthen Cellectis' position in gene editing, while analysts see a price target of $7.50 and the company, despite strong revenue growth, is not yet profitable. » Mais em de.investing.com
Cellectis reports strong phase‑1 data for leukemia therapy lasme‑cel
Cellectis released promising phase‑1 data from the BALLI‑01 study of lasme‑cel (UCART22) in relapsed/refractory B‑ALL: overall response rate 68% (manufacturing process 2), 83% at the dose recommended for phase‑2 and 100% in the phase‑2 target population. In that target group, 56% achieved complete remission (CR/CRi) and about 80% were minimal residual disease (MRD) negative; 78% of patients eligible for transplant received one. The therapy showed activity even in heavily pretreated patients and was generally well tolerated. Cellectis has initiated a registration‑enabling phase‑2 study (first patient expected Q4 2025) and is targeting a BLA submission in 2028; Q2 financials showed mixed signals with revenue above forecast but an EPS miss. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 3,76 mi | 89,30% |
| Ganho bruto | 1,27 mi | 96,13% |
| Ganho líquido | -61,47 mi | 10.537,01% |
| EBITDA | -27,79 mi | 460,63% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 71,53 mi |
Número de ações | 72,33 mi |
Máximo/mínimo de 52 semanas | € 4,75 - € 0,90 |
| Dividendos | Não |
Beta | 2,91 |
PER (PE Ratio) | -0,85 |
PEG (PEG Ratio) | 0,01 |
P/VC (PB Ratio) | -6,20 |
P/V (PS Ratio) | 3,12 |
Perfil da empresa
A Cellectis S.A., uma empresa biotecnológica em fase clínica, desenvolve produtos de imuno-oncologia baseados em linfócitos T editados por genes que expressam recetores de antigénio quiméricos para atingir e erradicar células cancerígenas. Opera através de dois segmentos, Terapêuticas e Plantas. A empresa está a desenvolver o UCART19, um candidato a produto de linfócitos T alogénicos para o tratamento de neoplasias hematológicas que expressam CD19, como a leucemia linfoblástica aguda; o ALLO-501 e o ALLO-501A para tratar o linfoma difuso de grandes células B recidivante/refratário e o linfoma folicular; o ALLO-316 para o tratamento do carcinoma de células renais; o UCART123 para o tratamento da leucemia mieloide aguda; e o UCART22 para tratar a leucemia linfoblástica aguda de células B. Está também a desenvolver o UCARTCS1 e o ALLO-715 para o tratamento do mieloma múltiplo. A empresa tem alianças estratégicas com a Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; e Iovance Biotherapeutics, bem como uma colaboração estratégica de investigação e desenvolvimento com a Cytovia Therapeutics, Inc. A Cellectis S.A. foi fundada em 1999 e tem sede em Paris, França.
| Nome | Cellectis |
| CEO | Andre Choulika |
| Sede | Paris,
if França |
| Site | |
| Entrada em bolsa | 07/02/2007 |
| Colaboradores | 227 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
Euronext | ALCLS.PA |
Pnk | CMVLF |
Frankfurt | ZVA.F |
Düsseldorf | ZVA.DU |
London | 0WA2.L |
Paris | ALCLS.PA |
München | ZVA.MU |